Background: To evaluate the utility of home spirometry (HS) versus office spirometry (OS) in assessing treatment response to azithromycin in bronchiolitis obliterans syndrome (BOS). Methods: 239 Lung transplant recipients were retrospectively studied. DFEV 1 AE 10% from FEV 1 at azithromycin initiation for !7 consecutive days in HS or !2 measures in OS were taken as cut-off for response or progression. Results: Based upon HS, 161/239 (67%) patients were progressive despite macrolide, 19 of who exhibited transient improvement in FEV 1 (11%). Time to progression was 29 (13e96) days earlier with HS than in OS. Forty-six (19%) recipients responded in HS after median 81 (22 e343) days, whilst 22% remained stable. Concordance in azithromycin treatment response between OS and HS was observed in 210 of 239 patients (88%). Response or stabilization conferred significant improvement in survival (p Z 0.005). Transient azithromycin responders demonstrated improved survival when compared to azithromycin refractory patients (p Z 0.034). Conclusions: HS identified azithromycin refractory patients significantly earlier than OS, possibly facilitating aggressive treatment escalation that may improve long-term outcome.
Introduction
Lung transplantation (LTx) has become an accepted therapeutic option for selected patients with end-stage lung disease. Post-transplant survival continues to improve, but mean 5-year survival remains disappointingly low at 53% [1] . Bronchiolitis obliterans syndrome (BOS) remains the leading cause of death beyond the first year after transplantation [1] , affecting almost half of all patients within 5 years. BOS is characterized by its unpredictable and variable clinical course, ranging from an insidious onset with gradual loss of pulmonary function over months to years, to an abrupt and severe decline in pulmonary function within a matter of weeks [2e4] . Whilst obliterative bronchiolitis is the presumed histopathological correlate, it is not consistently detectable by transbronchial biopsy and spirometry is routinely used as the agreed surrogate marker to diagnose and stage BOS [5] . Current treatment strategies for BOS include aggressive management of known risk factors as well as early identification of BOS and initiation of proposed treatments or re-transplantation.
Long-term azithromycin has been shown to improve FEV 1 and survival in up to 40% of BOS patients in various singlecenter studies [6e10] . Current data however, does not provide insight beyond initial response, with little being known about whether initial responders relapse later or whether non-responders stabilize after azithromycin initiation. Early azithromycin initiation prior to development of BOS stage 2 has been associated with a significant reduction in risk of death [9] , suggesting the possibility of critical therapeutic windows for efficacy of some treatment options.
Given these issues, prompt assessment for therapeutic response with a view to treatment escalation in progressive patients is vital. Previous studies involving lung transplant recipients have demonstrated the benefits of daily home spirometry (HS) in detecting early changes in graft function [11e16]. In the current study, home spirometry data was used to evaluate treatment response after commencing azithromycin in LTx patients with BOS to evaluate if macrolide-refractory progression could be identified earlier than the present system of office spirometry (OS).
Materials and methods
A single-center retrospective analysis of all adult lung transplant recipients between 2003 and 2011 commenced on long-term azithromycin for bronchiolitis obliterans was performed.
Only patients with adequate adherence to home spirometry (!50% prescribed measures) and at least one follow-up visit after azithromycin initiation were included. Recipients with severe airway complications, unknown start or interrupted azithromycin treatment were excluded (Fig. 1 ). All patients were followed-up from azithromycin initiation until death, re-transplantation or to completion of the study on May 31, 2011.
Home spirometry (HS)
Patients were instructed on using a home spirometry device and asked to perform daily testing, ensuring that attempts were made at the same time each day. All patients used a handheld electronic spirometry system (VIASYS â Healthcare, Hoechberg, Germany) that collected and stored relevant expiratory flowevolume parameters including FEV 1 . Following each attempt, a digital display on the spirometer indicated the current FEV 1 value along with a direct comparison to the patient's pre-programmed best FEV 1 . Based on a "traffic light" system, the device displays green when !90% best FEV 1 is achieved, yellow for <90% but !80% and red for <80% best FEV 1 . The device stores up to 450 measurements, which were routinely downloaded at each outpatient attendance and stored centrally in an electronic database. Patients were instructed to contact the transplant center within 24 h following a change in "colour" on the spirometer, regardless of symptoms.
Routine follow-up
Patients were followed-up at our specialized outpatient clinic with scheduled visits at 2-to 4-month intervals. Standard immunosuppression consisted of a triple-drug regimen including a calcineurin-inhibitor, prednisolone and either a cell-cycle-inhibitor or mTOR (mammalian target of rapamycin) inhibitor. After excluding alternate causes, azithromycin (as the standard neo-macrolide therapy) was commenced in all patients demonstrating a persistent deterioration in lung function below 80% baseline, with most patients receiving an initial loading dose of 500 mg daily for 3 days before continuing with 250 mg three times per week thereafter. Routine follow-up attendances included clinical examination, spirometry, capillary blood gas analysis and a chest x-ray. Bronchoscopy was routinely performed, based on interpretation of these findings to investigate suspected rejection, infection or airway complication.
BOS staging complied with the International Society of Heart and Lung Transplantation classification of bronchiolitis obliterans syndrome (BOS) [17] . Baseline FEV 1 was defined as the average of the two highest measurements obtained at least 3 weeks apart during postoperative course.
Restrictive allograft syndrome (RAS) was defined according to Sato et al. [18] . If TLC data were not available, RAS was defined by imaging (presence of parenchymal infiltrates) and the absence of an obstructive pattern in pulmonary function test (FEV/FVC > 0.7).
Interpretation of macrolide response
In home spirometry (HS), patients demonstrating a !10% FEV 1 increase (compared to FEV 1 at start of azithromycin) from the baseline value over a period of 7 consecutive days were termed responders. Patients with a !10% FEV 1 loss over 7 consecutive days were classified as progressive. All remaining patients with FEV 1 values between 91 and 109% were considered stabilized. Patients who initially fulfilled the responder criteria, but subsequently progressed to 90% FEV 1 during follow-up, were termed transient responders.
With regard to office spirometry (OS), the same cut-off values in %FEV 1 were used and considered relevant when arising in at least two consecutive OS measurements after excluding alternative causes. OS was performed in accordance to the published guidelines of the American Thoracic Society and European Respiratory Society [19] .
The date of progression or response in HS and OS was defined as the first occasion on which the cut-off values were reached.
Statistical analysis
Data are reported as medians with interquartile ranges (IQR) and all reported p values are two-sided unless otherwise stated. For all analyses, p-values <0.05 were considered statistically significant. Category variables were analysed using either a chi-squared test or Fisher's exact test. Medians were compared using the ManneWhitney test and the nonparametric KruskaleWallis-H test. Cohen's kappa coefficient was used as a measure of agreement for categorical items. Survival curves were constructed using Kaplan Meier method and compared using the log-rank test.
Results
Two hundred thirty-nine lung transplant recipients fulfilled inclusion criteria. Baseline characteristics of patients are listed in Table 1 . Median follow-up was 22 (11e37) months. Median FEV 1 at azithromycin initiation was 67% (54e77) baseline, 21% had a restrictive phenotype. Sixty-seven percent of patients (161/239) demonstrated progression in HS. Nineteen patients (19/239, 8%) had an initial response but progressed during follow-up after 501 (232e1334) days and were considered transient responders. No transient responder stabilized. Time to progression was 61 (24e149) days according to HS and 90 (37e245) days according to OS. HS detected progression on average 29 (13e96) days earlier than outpatient measures. Median loss of FEV 1 in all progressive patients was 0.4 L (À17%) at the first visit defining progress in OS.
Nineteen percent of patients (46/239) responded to azithromycin after 81 (22e343) days on HS, compared to 222 (64e551) days on OS. HS detected treatment response on average 141 (42e208) days earlier than office measures. Twenty-two percent of patients (51/239) exhibited stabilized lung function after commencing macrolides. Classification of azithromycin response was concordant between HS and OS in 210/239 (88%) patients (Fig. 2) .
Seven of 29 patients exhibiting disconcordance between HS an OS, demonstrated transient responses in HS. Of the remaining 22 patients, 5 were progressive and 17 were nonprogressive.
Sensitivity and specifity of HS in detecting progressive patients resulted in p values of 0.800 and 0.962 respectively. Positive predictive value (PPV) and negative predictive value (NPV) were p Z 0.863 and p Z 0.941. Sensitivity and specifity of HS in detecting responder resulted in p values of 0.833 and 0.944 respectively. Positive predictive value (PPV) and negative predictive value (NPV) were p Z 0.761 and p Z 0.964. Analysis of concordance between home and clinic spirometry resulted in K Seventy patients (29%) died during follow-up after 490 (258e1013) days, 59 (84%) in the HS-progressive group. Causes of death are shown in Table 1 . Five of 239 (2%) patients died from cardiovascular events (stroke n Z 1, STelevation myocardial infarction n Z 1, sudden cardiac death n Z 3). All patients dying following cardiac arrest had advanced chronic allograft dysfunction and were oxygen dependent. Thirteen patients (5%) underwent retransplantation, all of whom had been HS-progressive. In HS-progressive patients, 44 (75%) died from respiratory failure after 450 (215e989) days.
Median survival of all patients was 1952 (1228e3289) days after transplantation, 756 (379e1302) days after BOS onset and 673 (341e-1106) days after commencing azithromycin. KaplaneMeier survival estimates at 1 and 3 years after initiation of azithromycin was 91% and 74% for responders versus 69% and 41% for non-responders (p Z 0.005). Overall survival of progressive and nonprogressive patients is displayed Fig. 3 .
Worst survival occurred in the HS-progressive group with median survival of 1.0 (0.0e2.0) years. Transient azithromycin responders in HS demonstrated improved survival when compared to azithromycin -refractory patients (2.0; IQR1.0e4.0) years, p Z 0.034).
BOS onset of BOS was earlier in the progressive group, arising 31 (15e48) months post-transplant compared to 46 (22e73) months amongst non-progressive patients (p < 0.05). FEV 1 at azithromycin initiation was also lower 65% Best FEV 1 (IQR 51e75) vs. 70% (69e79) in the non- [15] . Our findings confirm high levels of concordance between home spirometry (HS) and office spirometry (OS). Despite these findings, we continue to support controlling OS 4 weeks after azithromycin initiation due to inadequate HS adherence in some patients. Difficulties in performing the forced expiratory maneuver were suspected in 60% of patients showing greater variability in HS measurements. Although patients were trained in using the home spirometer, the measurements were performed unsupervised, in contrast to OS which was supervised by experienced personnel, allowing direct correction of false technique.
In two thirds of observed discrepancies, trends in pulmonary function were not detected in HS. Additional training on how to perform HS when recipients are being prepared for hospital discharge may improve patient adherence and further improve concordance between HS and OS. We have previously observed greatest adherence rates with HS in the initial year following transplantation, with a subsequent decrease over time [20] . Annual training updates, reiterating the importance and technique of HS may improve adherence in long-term transplant recipients.
Less than 5% of patients were identified as transient responders or stable in HS, while OS demonstrated progression. It is unsurprising that OS proved less sensitive in identifying transient responders. Temporary improvements in pulmonary function occurring between visits could be potentially missed, in contrast to daily measurements in HS. In half of transient responders, increases in HS FEV 1 appeared implausible, suggesting alternative explanations including that another person may have performed HS on the device.
According to various reports, approximately 35% of patients in different BOS stages respond to macrolide treatment [6,7,21e25] . There exists however no uniform definition of response, and most studies made no distinction between long-term and transient response. Our response rates appear lower and a greater proportion treatment initiation in advanced BOS stages (2 or 3) compared to the largest study [8] .
Azithromycin was prescribed at 250 mg orally three times per week, in concordance with the majority of published studies [6, 8, 21, 22] , including our own experiences [25] . Very high tissue concentrations, high lipid solubility in combination with a long half-time allow such treatment protocols. To optimize patient adherence we recommended fixed-dosing (MondayeWednesdayeFriday) rather than alternate days. Current experience in CF-populations has demonstrated, that if 250 mg is not effective, higher doses are also generally ineffective and resulted in increased side-effects [20] . Commonest side-effects included nausea, vomiting, diarrhea or abdominal pain. Gastrointestinal intolerance was greatest in daily treatment protocols [30] . In our experience, prolonged use of azithromycin is well tolerated, with at most mild side-effects. No ventricular arrhythmias were observed in our cohort. This may be explained by LTx recipients being typically younger, with proven absence of cardiac disease in contrast to elderly patients with cardiovascular risk factors [31] . Nevertheless 5/239 (2%) patients died from cardiovascular events (stroke n Z 1, ST-elevation myocardial infarction n Z 1, sudden cardiac death n Z 3). Currently we recommend QTc monitoring prior to initiation and regularly during long-term azithromycin along with avoidance of other QTc prolonging drugs.
In accordance with previous studies, macrolide responders demonstrate significantly better overall survival compared to non-responders [8, 9] . Interestingly, survival in patients exhibiting a sustained response was similar to those demonstrating a transient response and non-response with stable FEV 1 . This may reflect a more benign disease course. Our findings emphasize that even short-term response and stabilization confer patient benefit. Improved functional reserve afforded by short-term response and lung function stabilization may facilitate a more favorable BOS course. In macrolide-refractory patients alternative treatments such as extracorporeal photopheresis [26] , total lymphoid irradiation [27] , montelukast [28] , anti-reflux treatment or retransplantation remain possible treatment options. Regarding additional clinical risk factors such as gramnegative airway colonization or co-medication, no significant differences between progressive and non-progressive patients were observed.
Additional factors may limit the conclusions beyond the retrospective single-center nature of the study. Bias may exist in patient adherence due to selection criteria (patients without HS and non-adherent patients were not evaluated). Addition of further BOS treatment options following macrolide initiation such as extracorporeal photopheresis [26] , total lymphoid irradiation [27] or montelukast [28] were not considered.
In conclusion, HS appears to be a safe and reliable tool in facilitating assessment of treatment response in patients with BOS commenced on azithromycin. HS detects macrolide-refractory BOS significantly earlier and might help optimize treatment escalation through other available treatments or consideration for re-transplantation. Patients may be instructed to contact their transplant center when a significant decline in FEV 1 is evident on their HS device. Changes in HS should then be confirmed by OS. When long-term use of macrolides is indicated, we recommend outpatient reassessment of treatment response 4 weeks after treatment initiation. Patients with progressive lung function decline detected by OS or HS despite azithromycin therapy should be considered for early escalation of BOS therapy. It remains conceivable, that azithromycin also confers a more favorable BOS clinical course in these patients. Given that BOS is life-threatening, with no superior alternative treatment, we routinely continue long-term azithromycin in patients who stabilize and even in progressive patients if well tolerated. In general, patients decline treatment cessation due to anxiety of further acceleration in FEV 1 decline. 
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